Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.
The conversation discusses whether RU58841, if FDA approved and safe, would be recommended over finasteride for hair loss. Specific treatments mentioned include RU58841, finasteride, and minoxidil.
A user is frustrated about early balding despite older male relatives retaining hair into old age. Another user plans to start finasteride soon to address their hair thinning.
The user is considering adding RU58841 to liquid minoxidil without propylene glycol (PG) due to an allergy and is asking if this combination is effective and if PG is necessary. They have been using finasteride and minoxidil foam, plan to use RU58841 with liquid minoxidil in the evening, and continue finasteride.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
The user experienced high estradiol levels after using topical finasteride at 0.1 mg/day, which normalized after discontinuation. They are questioning if this low dosage could significantly impact hormone levels.